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Executive Summary 
The Dr. Robert Bree Collaborative was established in 2011 to provide a forum in which public and 
private health care stakeholders can work together to improve quality, health outcomes, and cost-
effectiveness of care in Washington State. Alzheimer’s disease and other dementias are a growing 
concern in Washington State and around the country. The complex symptoms including in memory, 
cognition, and social functioning are difficult for patients themselves, their family members and friends, 
and the health care system at large. In many cases no clear guidelines exist to support the patient 
through diagnosis and increase in symptoms. The Bree Collaborative elected to address this topic and 
convened a workgroup to develop recommendations that met from January 2017 to November 2017. 
This Report and Recommendations has six focus areas developed in partnership with the Dementia 
Action Collaborative: 
1. Diagnosis,  
2. Ongoing care and support,  
3. Advance care planning and palliative care,  
4. Need for increased support and/or higher levels of care,  
5. Preparing for potential hospitalization, and  
6. Screening for delirium risk.  
The goal of the recommendations are to support patients, their family members, and other caregivers 
across the disease process. The workgroup developed a roadmap for implementation starting on page 5 
outlining the patient perspective for optimal care alongside operational details for each of the six areas 
walking through the current state, intermediate steps toward implementation of the recommendations, 
and a description of optimal care. Following this on page 12 are specific steps for stakeholder groups 
including: patients and family members, primary care practices and systems (including primary care 
providers), health plans, hospitals, skilled nursing facilities, and Washington State agencies to improve 
quality of dementia care, health outcomes of people with dementia and their caregivers, and 
affordability.  
The remainder of this Report is meant to support these six focus areas including discussions of the 
evidence and best practices for diagnosis, how to best support patients and families through disease 
progression, linking these recommendations to earlier Bree Collaborative work around advance care 
planning and palliative care, and information on transitions of care and delirium. The Report also 
discusses other work within Washington State to facilitate high-quality dementia care including 
development of the Washington State Plan to Address Alzheimer's Disease and Other Dementias and 
ending with an inclusion of dementia-specific measures. 
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Dr. Robert Bree Collaborative Background 
The Dr. Robert Bree Collaborative was established in 2011 by Washington State House Bill 1311 “…to 
provide a mechanism through which public and private health care stakeholders can work together to 
improve quality, health outcomes, and cost effectiveness of care in Washington State.” The Bree 
Collaborative was modeled after the Washington State Advanced Imaging Management (AIM) project 
and named in memory of Dr. Robert Bree, a pioneer in the imaging field and a key member of the AIM 
project. 
Members are appointed by the Washington State Governor and include public health care purchasers 
for Washington State, private health care purchasers (employers and union trusts), health plans, 
physicians and other health care providers, hospitals, and quality improvement organizations. The Bree 
Collaborative is charged with identifying up to three health care services annually that have substantial 
variation in practice patterns, high utilization trends in Washington State, or patient safety issues. For 
each health care service, the Bree Collaborative identifies and recommends best-practice, evidence-
based approaches that build upon existing efforts and quality improvement activities to decrease 
variation.  In the bill, the legislature does not authorize agreements among competing health care 
providers or health carriers as to the price or specific level of reimbursement for health care services. 
Furthermore, it is not the intent of the legislature to mandate payment or coverage decisions by private 
health care purchasers or carriers.   
See Appendix A for a list of current Bree Collaborative members.   
Recommendations are sent to the Washington State Health Care Authority for review and approval. The 
Health Care Authority (HCA) oversees Washington State’s largest health care purchasers, Medicaid and 
the Public Employees Benefits Board Program, as well as other programs. The HCA uses the 
recommendations to guide state purchasing for these programs. The Bree Collaborative also strives to 
develop recommendations to improve patient health, health care service quality, and the affordability of 
health care for the private sector but does not have the authority to mandate implementation of 
recommendations. 
For more information about the Bree Collaborative, please visit: www.breecollaborative.org.  
Alzheimer’s disease and other dementias are a growing concern in Washington State and around the 
country. The complex symptoms including memory, cognition, and social functioning are difficult for 
patients themselves, their family members and friends, and the health care system at large. In many 
cases no clear guidelines exist to support the patient through diagnosis and increase in symptoms. The 
Bree Collaborative elected to address this topic and a workgroup convened to develop 
recommendations from January 2017 to November 2017.  
See Appendix B for the Alzheimer’s Disease and Other Dementias workgroup charter and a list 
of members.  
See Appendix C for results of the Guideline and Systematic Review Search Results. 
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Purpose Statement  
The decline in memory and other cognitive functions and corresponding loss of independence because 
of dementia is a growing concern in our aging population. Age is the biggest risk factor for dementia 
with prevalence rates of 13.9% in those 71 and older increasing to 37.4% for those 90 and older.1 The 
majority of cases, 69.9%, are due to Alzheimer’s disease with vascular dementia (also known as post-
stroke dementia) accounting for 17.4% and the remaining 12.7% due to a combination of Parkinson’s 
dementia, normal-pressure hydrocephalus, frontal lobe dementia, alcoholic dementia, traumatic brain 
injury, Lewy body dementia, or being of unknown origin.1 Hearing loss, associated with increasing age, is 
also associated with cognitive decline and increased risk of dementia.2 Washington State has the third 
highest rate of death from Alzheimer’s disease of any state and Alzheimer’s is the third highest age-
adjusted cause of death within the State overall.3 The number of people diagnosed with dementia is 
expected to increase 40% in next 10 years and 181% over the next 30 years.3  
 
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines dementia as 
decline from previous level of performance in learning and memory, language, executive function, 
complex attention, perceptual-motor, and/or social cognition that interfere with independence in 
everyday activities absent another cause (e.g., depression, in the context of delirium).4 Dementia can 
impact ability to plan and carry out activities, manage work and personal finances, and take 
medications.5 Severe dementia is associated with greater prevalence of behavioral and psychological 
symptoms including agitation, anxiety, depression, delusions, and sleep or appetite changes.6 These 
behavioral and psychological symptoms are complex and can be the most difficult for family members 
and other caregivers.7 Dementia also can result in a higher risk of falls at home, hospitalizations, and risk 
of falls within a hospital setting.8.9 Dementia is associated with higher out of pocket expenses, that 
increase with the severity of the diagnosis, especially for hospital or nursing home care and prescription 
medications.8,9 Additionally, dementia is a terminal condition that lends itself well to palliative care 
services.  
In many practices in Washington State, there are no guidelines to increase quality of 
care for diagnosis or care for patients with Alzheimer’s disease and other 
dementias.10 This is costly to the health care system and overly burdensome to 
primary care clinicians, and patients, their caregivers, and the community.  
 
The Bree Collaborative Alzheimer’s Disease and Other Dementias Workgroup endorses and aims to build 
off the previous work within Washington State, specifically the Washington State Plan to Address 
Alzheimer's Disease and Other Dementia. The workgroup aims to align care delivery with the existing 
evidence-based standard of care for each stage of disease and across health care settings for both for 
patients and their families and caregivers. The workgroup seeks to address the variation in quality of 
treatment across the state of Washington through implementation of these standards and build a health 
care system that is responsive to individual patient and family need as well as being equitable.  
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Recommendations  
The Bree Collaborative Alzheimer’s Disease and Other Dementias workgroup has developed 
recommendations in six areas: (1) diagnosis, (2) ongoing care and support, (3) advance care planning 
and palliative care, (4) need for increased support and/or higher levels of care, (5) preparing for 
potential hospitalization, and (6) screening for delirium risk. This recommendation is developed in 
partnership with the Dementia Action Collaborative and seeks to build off the work of the health and 
medical subcommittee. Alzheimer’s disease and other dementias occur in all cultural and ethnic groups 
and must be addressed in a culturally-sensitive manner.  
The workgroup defines dementia as outlined by the National Institute on Aging and the Alzheimer’s 
Association including symptoms that:11 
 “Interfere with the ability to function at work or at usual activities; and 
 Represent a decline from previous levels of functioning and performing; and 
 Are not explained by delirium or major psychiatric disorder; 
 Cognitive impairment is detected and diagnosed through a combination of (1) history-taking from the 
patient and a knowledgeable informant and (2) an objective cognitive assessment, either a “bedside” 
mental status examination or neuropsychological testing. Neuropsychological testing should be performed 
when the routine history and bedside mental status examination cannot provide a confident diagnosis  
 The cognitive or behavioral impairment involves a minimum of two of the following domains 
o Impaired ability to acquire and remember new information––symptoms include: repetitive 
questions or conversations, misplacing personal belongings, forgetting events or appointments, 
getting lost on a familiar route. 
o  Impaired reasoning and handling of complex tasks, poor judgment––symptoms include: poor 
understanding of safety risks, inability to manage finances, poor decision-making ability, inability 
to plan complex or sequential activities. 
o  Impaired visuospatial abilities––symptoms include: inability to recognize faces or common 
objects or to find objects in direct view despite good acuity, inability to operate simple 
implements, or orient clothing to the body. 
o  Impaired language functions (speaking, reading, writing)––symptoms include: difficulty thinking 
of common words while speaking, hesitations; speech, spelling, and writing errors. 
o  Changes in personality, behavior, or comportment–– symptoms include: uncharacteristic mood 
fluctuations such as agitation, impaired motivation, initiative, apathy, loss of drive, social 
withdrawal, decreased interest in previous activities, loss of empathy, compulsive or obsessive 
behaviors, socially unacceptable behaviors.” 
We found it helpful to ground all six focus areas in the patient perspective to keep the patient at the 
center of care improvement. On the following pages we outline the patient perspective alongside 
operational details for each of the six areas walking through the current state, intermediate steps 
toward implementation of the recommendations, and a description of optimal care. 
Following this on page 12 are specific steps for stakeholder groups including: patients and family 
members, primary care practices and systems (including primary care providers), health plans, hospitals, 
skilled nursing facilities, and Washington State agencies to improve quality of dementia care, health 
outcomes of people with dementia and their caregivers, and affordability.   
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Table 1: Recommendations for Optimal Alzheimer’s Disease and Other Dementia Care 
 Focus Area Patient Perspective Operational Details 
1 Diagnosis  I or my family members 
have concerns about 
memory. My care team 
talks with me about my 
concerns and helps me 
understand the cause of 
any trouble with thinking 
ability. I know who to 
contact in case of urgent 
questions or situations 
and have thought about 
the type of care that I 
would want at different 
stages of the disease.  
Current State: While some providers may routinely screen for or discuss cognitive issues with 
patients, in many cases issues with memory and cognition are only addressed if they are 
brought up by the patient or family member(s). Once brought up by the patient or family 
member, issues with memory or cognition may be adequately addressed by the provider. In 
some cases there may be no clinical follow-up. The provider may be unsure as to screening 
tools, how to utilize the Medicare Annual Wellness Visit, or next steps and may not feel 
comfortable discussing cognitive issues due to lack of training and lack of a system-wide 
protocol for addressing cognitive concerns. Primary care providers may diagnose dementia or 
may refer to a specialist (i.e., neurologist, geriatric psychiatrist) for diagnosis if one is available 
within the health care system. Specialty consultation may be unavailable. 
Intermediate Steps: Practices work to increase providers’ level of comfort and expertise in 
diagnosing and discussing a dementia diagnosis, increasing understanding that this diagnosis is 
within the primary care scope of practice. Clear guidelines are available on how to make the 
diagnosis using validated tools with the expectation that the provider will truthfully discuss the 
diagnosis with the patient and family and record the diagnosis in the medical record.  Practices 
may pilot screening programs with select populations, reporting on lessons learned before 
implementing wider screening. Primary care providers involve a neurologist or other specialist 
as needed for consultation and support or for differential diagnosis.   
Optimal Care:  
 The patient has an identified primary care provider.  
 Patient and family members receive coordinated care as part of an interdisciplinary 
team that has been trained in how to talk about cognitive impairment. This may 
include support staff in the primary care provider office, specialists such as neurology 
consultation, and community partners.  
 Family members or other caregivers are included in conversations and feel supported 
and heard.  
 Primary care providers are clear on the value of early detection and feel comfortable 
truthfully discussing cognitive issues, understanding the uncertainty that can 
accompany the diagnosis. Mild cognitive impairment (MCI) or dementia is detected at 
an early stage.  
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 Hearing loss is assessed and appropriately addressed (e.g., hearing aids, personal 
amplifiers) as hearing loss can complicate identification and treatment.  
 Diagnosis follows a two-stage clear clinical protocol with initial screening through the 
Medicare Annual Wellness visit or other visit in which cognitive impairment is detected 
with a brief (<5 minutes), validated tool. Direct observation with consideration of 
information obtained by family members, friends, or others may also be used.  
o A positive finding is followed by additional evaluation and confirmation of the 
diagnosis, if needed. Diagnosis follows the Alzheimer’s Association Medicare 
Annual Wellness Visit Algorithm for Assessment of Cognition outlined in 
Appendix D and in a Clinical Provider Practice Tool outlined here.  
o The diagnosis conversation and any subsequent conversations follow the 
Alzheimer’s Association principles for a dignified diagnosis, listed in Appendix 
E, and includes an advance care planning conversation (see #4). CPT code 
99483 (i.e., detailed structural assessment of dementia or Alzheimer’s disease 
performed by a clinician that cannot be done the same day as an office visit) 
can be billed for care planning services provided to individuals with cognitive 
impairment. 
2 Ongoing Care and 
Support/Manage
ment 
Once I have a diagnosis, I 
and my family members 
feel hopeful that we/I can 
manage my cognitive 
diagnosis with my care 
team and family 
member(s). 
Current State: Patients experience significant variability in the type and number of 
interventions and support offered after diagnosis and throughout the disease course.  Patients 
and families are not consistently informed of treatment options, community services, or an 
answer to the question “I have a diagnosis, what do I do now?” and can feel lost. Providers 
may be unaware of the supports available in their community or there may be a lack of 
community support and providers are uncertain as to next steps.  
Intermediate Steps: The practice has a pilot pathway for interventions and supports to offer at 
different stages throughout the disease process that may not be used for all appropriate 
patients. Family and caregivers may be part of the initial conversation, but may not feel 
supported throughout the disease process.  
Optimal Care:  
 Patients are often best supported by a care team framework. The care team may 
include providers outside of the practice (e.g., specialty care). Patients and family 
members are included as part of the care team with patient goals and values being 
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incorporated into the type of interventions offered as well as consideration for 
comorbid conditions.  
 Primary care teams routinely assess complexities of supporting patients with dementia 
and the needs of family care partners for enhanced support.  
 Dementia care management services (e.g., home health, phone-support, enhanced 
outpatient management) are offered to patients or caregivers who have been 
determined to be high-risk. This high-risk group may include patients that have several 
medical comorbidities, complex medication regiments, behavioral/psychiatric 
symptoms, and/or history of frequent utilization of acute care services.  Care 
management services to consider may include: comprehensive in-home assessment by 
trained health care professionals; collaborative goal-setting between clinicians, care 
partners and patients; close follow-up and coordination of medical and psychosocial 
services and routine assessment of needs. 
 Providers routinely consider a patient’s dementia diagnosis and comorbid conditions 
when making decisions to minimize unnecessary or harmful care. Providers 
appropriately treat conditions that can worsen symptoms or lead to poor outcomes, 
including depression and existing medical issues. 
 The care team is able to maximize functioning to meet patient and family needs at 
each stage of the disease.  
 Evidence-based interventions (e.g., exercise, diet modification) are suggested upon 
diagnosis and discussed during any follow-up visits. The care team assess and discusses 
with the patient and family how to reduce risk of falls, how to optimize function and  
mitigate confusion, how to manage medication(s), and how to address driving status 
and safety (outlined here).  
 The level of support offered depends on patient-factors including complexity, severity, 
level of caregiver support, and other factors.  
 Neuropsychiatric symptoms (e.g., agitation, psychosis) may be due to social, 
psychological, or environmental factors and management should be discussed using a 
shared-decision making approach. Non-pharmacologic approaches are best attempted 
first; pharmacological therapies are not a first line therapy. 
 Patients and families are offered information about available community supports 
such as through the Alzheimer’s Association and local Area Agency on Aging programs. 
 Patient quality of life is maximized through a focus on individuals’ preserved 
capabilities and identities, access to services that prolong functioning (e.g., speech, 
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occupational, physical therapies hearing aids or personal amplifiers), and continued 
engagement with social networks and enriching activities, through use of a strengths-
based approach.  
 Caregivers are supported and providers assess and note caregiver knowledge, skills, 
capacity and possible distress at each visit. Caregivers are also connected with 
resources such as county Family Caregiver Support Programs, which facilitate access to 
respite care, and support groups, if available.  
3 Advance Care 
Planning and 
Palliative Care 
I have had a meaningful 
conversation with my 
doctor, including my 
family member(s), about 
what I want for end-of-life 
care. We have written this 
down into an advance 
directive that is accessible 
by my care team and 
family. I feel confident 
that my goals of care will 
be followed. If I need it, I 
have access to and 
understand the need for 
palliative care.  
Current State: Care given to patients at the end of life varies based on institutional protocol 
and is not necessarily aligned with patient goals of care. Family and other caregivers may feel 
burdened in making clinical decisions without having had previous conversations with the 
patient and feel overwhelmed and unsupported. Patient symptoms (e.g., pain) may not be 
well-managed or addressed. Non-value added care may be provided, such as mammograms or 
feeding tube placement in patients with advanced dementia. 
Intermediate Steps: Patient and family members have begun to have conversations about 
goals for care but may not have had these in a clinical setting and have not documented their 
goals in an advance directive or the advance directive is not accessible to the care team.  
Optimal Care:  
 Patients, providers, family, and other caregivers have had a comprehensive advance 
care planning conversation in a clinical setting that has been documented in an 
advance directive as early as possible to maximize the patient’s voice and input. This 
stipulates specific treatment preferences (if known and applicable to the situation), a 
durable power of attorney for health care that names a surrogate and indicates the 
amount of leeway the surrogate should have in decision-making; a written personal 
statement that articulates the patient’s values and goals regarding end-of-life care; 
discussion of risks, benefits, and goals for a potential hospitalization; and Physician 
Orders for Life Sustaining Treatment (POLST).  
 Providers routinely consider patient’s dementia diagnosis and issues of decision-
making capacity when making decisions to minimize unnecessary or harmful care and 
discuss this with the patient and family.  
 The care team has discussed when palliative care and/or hospice might be 
appropriate.  
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 The patient and family know who to contact if symptoms (e.g., pain) develop or 
worsen and feel confident in their care plan.  
4 Need for 
Increased Support 
and/or Higher 
Levels of Care 
I and my family members 
have a plan if my cognitive 
decline and care is more 
than can be managed 







Current State: For most patients and families there is little information about planning for 
possible transitions to higher levels of care. Providers and care teams may be unsure as to 
community supports available to patients and families and not know how to identify proactive 
steps to take (e.g., additional home support, residential care). 
Intermediate Steps: Initial conversations about the diagnosis include information about 
progression of cognitive decline and changes in functional abilities. Patients and family 
members are encouraged to start thinking about potential need for higher levels of care at 
home or in an alternative living situation. Patients and families are connected to community 
resources that provide education about these care options and understand how to manage 
behavioral symptoms as much as possible.  
Optimal Care:  
 Patients and family members understand that they may face decisions about the need 
for increased care, care transitions and/or increased stress and caregiver burden. 
Patients and families have these conversations early on in the disease, anticipating 
progression and have a plan if care needs are greater than can be safely managed at 
home with current supports, such as additional in-home care or services, respite care, 
or move to a residential facility.  
 From the time of initial diagnosis, patients and family members are connected to 
community resources that can help plan for future and increasing care needs.  
 Monitoring for progression of cognitive decline, emergence of behavioral symptoms, 
functional impairment (e.g., activities of daily living), and care-partner/family capacity 
is part of each primary care visit and communicated to the patient and family 
members.  
 Planning includes consideration for caregiver stress and capacity, financial and 
insurance concerns (e.g., long term care coverage), health care considerations, and 
availability of local residential facilities, paid caregivers, and community resources 
(such as Meals on Wheels, volunteer chore services, etc.). 
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5 Preparing for 
Potential 
Hospitalization  
I and my family 
understand that I may 
need to receive care from 
a hospital and have 
planned ahead for a 
potential hospital visit. 
After leaving the hospital, 
I and my family know our 
next steps – whether that 
is continuing to live at 
home or receiving care at 
a residential facility – and 
have enough information 
to make a decision 
comfortably.  
Current Care: Hospitalization or a visit to an emergency room may feel unexpected to patients 
and family members. Clinicians and hospital staff may be unaware of the dementia diagnosis 
or any patient communication issues and may be unprepared for preventing patient safety 
issues such as agitation, delirium or adverse reactions to medications.  At discharge, patients 
and families may feel unsupported in managing symptoms at home or unsure about transitions 
to residential care or a rehabilitation facility.  
Intermediate Steps: Patients and families begin to have conversations about how to plan and 
prepare for a potential hospitalization. Hospitals have plans on how to incorporate relevant 
personal information (e.g., dementia diagnosis) into the electronic health record (EHR), 
procedures performed and care provided during the hospitalization (e.g., anesthesia and pain 
protocols), and how to communicate this diagnosis to staff. Discharge protocols identify family 
caregivers and take into consideration needs of patients with dementia and how to support 
patients either being discharged to home or to a residential care facility.  
Optimal Care:  
 Patients and family members have had conversations early on in the disease process to 
address patient wishes for hospital visits and medical intervention including risks and 
benefits of hospitalization. This may include using a POLST.  
 Family and other caregivers understand red flags that may necessitate entry into an 
acute care setting and understand how to implement the previously developed care 
plan if the patient is unable to express his or her wishes.  
 All treating clinicians and other staff are aware of the dementia diagnosis and 
understand the patient’s communication ability, ability to hear, behavioral concerns 
(e.g., agitation, exit seeking, wandering), and other information that the patient may 
not be able to communicate (e.g., allergies, other reactions to medications, dietary 
preference).  
 At discharge, the patient and family members are supported whether the patient is 
going home, to their prior facility, or to a residential care facility. Discharge planners 
facilitate discharge to the most appropriate location given an assessment of the 
patient’s current status (which may have changed since hospitalization), care partner 
or facility’s ability to meet needs, and rehabilitation potential.   
 The hospital team communicates with the facility or caregiver discharge instructions, 
current medications, and follow-up appointment needs.     
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6 Screening for 
Delirium Risk  
In a hospital, my care 
team asks me questions to 
see whether confusion and 
lack of independence will 
be an issue, especially 
after surgery. I understand 
what this might mean for 
me and my recovery.   
Current Care: Screening for delirium or incorporation of a patient’s dementia diagnosis into 
the medical record is not a routine part of hospital care.  
Intermediate Steps: Practices and hospitals may develop a pilot project to incorporate 
screening for delirium into a specific pre-surgical care pathway (e.g., total joint replacement) 
with eventual plans to learn from implementation and spread the protocol to all admissions.  
Optimal Care:  
 During hospitalization, all patients 65 years of age or older or with other identifiable 
risk factors are screened for risk of delirium. Results are incorporated into the medical 
record and the care team is aware of risk.  
 The patient as well as their family and other caregivers are made aware of the risk of 
delirium, what symptoms might look and feel like, and what delirium might mean for 
recovery.  
 Hospitals and providers implement care plans and protocols to minimize risk for 
delirium and have established plans to respond appropriately when it occurs. 
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Recommendations for Stakeholder Actions and Quality Improvement Strategies 
Persons with Memory Loss and Family Members  
Diagnosis 
 Talk to your health care providers about any concerns you might have about memory or thinking 
ability. Your care team should ask you a standard set of questions and may set up a follow-up 
appointment.  
 Talk to your health care providers about any concerns you have about being able to hear. If you 
do have hearing impairment, talk about hearing aids or an assisted listening device (e.g., pocket 
talker).  
o Information on identifying symptoms of hearing loss here  
o Information on how to communicate with someone who has hearing loss here  
 Make sure you can identify your primary care provider or family doctor.  
 Review the resources developed by the Washington State Dementia Action Collaborative 
especially the Dementia Road Map: A Guide for Family and Care Partners. This tool takes 
patients and caregivers in all stages of cognitive decline through action steps and questions from 
the early stages of being worried and wondering to late-stage dementia.  
 During diagnosis we recommend that your health care provider follow the principles outlined in 
the Alzheimer’s Association’s Principles for a Dignified Diagnosis. You can see these principles 
that have been developed by patients here and also listed in Appendix E on page 36.  
 Ask your care team about local resources. Connect to others in your community who may be 
going through the same process. Some resources include: 
o The county’s Area Agency on Aging provider (including referrals for family and caregiver 
support such as respite care facilities) 
o African American Elders Program 
o Alzheimer’s Association of Washington State 
o Alzheimer Society of Washington  
o American Association of Retired Persons (AARP) 
o American Automobile Association (AAA) Senior Drivers  
o Chinese Information and Service Center 
o Community Living Connections including resources by county 
o Hearing Loss Association of America - Washington State Association (HLA-WA) 
o Momentia Seattle 
o National Institute on Aging  
o Open Doors for Multicultural Families 
o Seattle Indian Health Board 
o Path with Art 
o Washington State Department of Social and Health Services - Office of the Deaf and 
Hard of Hearing 
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Ongoing Care and Support/Management 
 Talk with your care team about how to maintain quality of life and what this means to you and 
your family. Including concerns about: 
o Progression of cognitive decline 
o Managing other diagnoses that you might have (e.g., diabetes, high blood pressure, 
hearing loss) 
o Driving status and safety (outlined here) 
o Home safety and risk of falls 
o Feeling down or depressed 
o Confusion, agitation, aggression, and/or wandering  
o Sleep quality and sleep disturbance  
o Managing medications 
o Ability of your care partner/family to meet your care needs now and in the future 
o Whether palliative care or hospice might be appropriate  
o Any other concerns 
 Consider lifestyle changes as recommended by your care team (e.g., cardiovascular exercise, 
mindful changes to diet). 
Advance Care Planning. Think about the type of care you would want at the end of life. Have a 
conversation with your family members or other caregivers about what you would want. You should 
also have a conversation with your care team about your wishes, goals, and values for end-of-life care 
that includes caregivers and the individual designated as your durable power of attorney for health care.  
 You should complete:  
o An advance directive that stipulates specific treatment preferences (if known and 
applicable to the situation),  
o A durable power of attorney for health care that names a surrogate and indicates the 
amount of leeway the surrogate should have in decision-making, and  
o A written personal statement that articulates your values and goals regarding end-of-life 
care. 
o Physician Orders for Life-Sustaining Treatment (POLST) 
 There are many resources out there to help people have this conversation including:  
o Alzheimer’s Association End-of-Life Decisions (specific to dementia)  
o Death Over Dinner 
o The Conversation Project (specific to dementia) 
o End of Life Washington – Alzheimer’s Disease/Dementia Mental Health Advance 
Directive 
o Five Wishes 
o Honoring Choices Pacific Northwest 
o US National Library of Medicine Medline Plus  
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Planning for Higher Care Needs and Hospitalizations  
 Have conversations early on in disease progression about your wishes for hospital visits and 
medical intervention. Conversations should include risks and benefits of hospitalization and may 
include filling out a Physician Order for Life Sustaining Treatment also known as POLST. As part 
of these conversations, think about the type of care that you would not want (e.g., feeding 
tubes). Information from Choosing Wisely and Consumer Reports on feeding tubes can be found 
here. 
 Write down your wishes into a care plan with family and other caregivers. Talk about how family 
members or other caregivers should implement the care plan if you are unable to express your 
wishes.  
 Be sure that you and your family or other caregivers understand red flags that may mean you 
need to go to the hospital and under what conditions you may not want to receive care in the 
hospital setting.  
 Talk about the potential need for a higher level of care (e.g., more help at home) if care needs 
are greater than can be safely managed. Conversations should include financial as well as 
medical concerns.  
 Connect to community resources or state resources that can help plan for future and increasing 
care needs including respite care. 
 Discuss palliative care with your care team as well as whether or not hospice care might be 
appropriate.  
 Pack an emergency bag that can help make a hospitalization less stressful. This “to go” bag 
might include:12 
o Copies of insurance cards 
o List of medical conditions, medications, and allergies 
o Your primary care provider’s name and contact information 
o Your advance directive or POLST order 
o Other personal information such as name and preferred language, need for glasses, 
dentures, or hearing aids. 
o Snacks or water 
o Incontinence briefs, if usually worn, moist wipes, and plastic bags 
o Comforting objects or music player with earphones 
o A change of clothing, toiletries, and personal medications for yourself 
o Pain medicine, such as ibuprofen, acetaminophen, or aspirin—a trip to the emergency 
room may take longer than you think, and stress can lead to a headache or other 
symptoms 
o A pad of paper and pen to write down information and directions given to you by 
hospital staff 
o A small amount of cash 
o A note on the outside of the emergency bag to remind you to take your cell phone and 
charger with you. More information here. 
 Caregiving can be stressful. Talk to your provider about your needs as a caregiver. More 
information here.
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Primary Care Practices and Systems (including Primary Care Providers) 
Review Table 1 
Diagnosis 
 Identify the patient’s primary care provider and be sure the patient and family members know 
who this is.  
 Provide care as part of an interdisciplinary team where all members have been trained in how to 
talk about a dementia diagnosis that is tailored to the patient’s individual and cultural needs and 
goals of care including language. This may include support staff in primary care provider office, 
specialists such as neurology consultation, and community partners. The patient and family or 
other caregivers should be included as part of the care team and supported along with the 
patient. 
 Assess for and appropriately address hearing loss (e.g., hearing aids, personal amplifiers). 
Hearing loss can complicate dementia identification and treatment. 
 When talking to patients and family members, follow the Alzheimer’s Association’s Principles for 
a Dignified Diagnosis in Appendix E. Be truthful about any diagnosis. At the patient’s request, 
purposefully include family members or other caregivers in any conversation and work to be 
sure they feel supported and that their concerns are heard as well as those of the patient.  
 Work with information technology, billing/coding and other practice resources to add the CPT 
code 99483 to your electronic health record and learn how to use it. More information here.  
o Information on Medicare’s Cognitive Impairment Assessment and Care Planning Code, 
CPT code 99483 (Alzheimer’s Association Expert Task Force Recommendations and Tools 
for Implementation) here. 
o Information including tools and instructions on how to screen, assessment tools 
including NPI-Q, a Behavior Screen, Safety Assessment/Guide, Caregiver Profile/stress, 
End-of Life Checklist here. 
o General information here. 
 Institute a two-step process for diagnosis supported by a clear, clinical protocol. Support and 
train providers and staff on the value of early detection, how to comfortably talk about 
dementia, and on the uncertainty that can accompany the diagnosis. Refer to the Position Paper 
from the Dementia Action Collaborative for guidance. 
o First Step: Initial screening through the Medicare Annual Wellness visit (if Medicare) or 
other visit (Medicaid, private insurance). Follow steps as outlined in the Alzheimer’s 
Association Medicare Annual Wellness Visit Algorithm for Assessment of Cognition in 
Appendix D. Use a brief (<5 minutes), validated tool or direct observation with 
consideration of information obtained by family members, friends or others when 
screening.  
o Second Step: A positive finding results in a follow-up visit with additional evaluation and 
confirmation of the diagnosis, if needed. This follow-up visit may use the CPT code 
99483 (i.e., detailed structural assessment of dementia or Alzheimer’s disease 
performed by a clinician that cannot be done the same day as an office visit).13 
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 Include family members or other caregivers as identified by the patient in the 
conversation.  
 Have an empathetic, realistic, and patient- and family-centered (e.g., using 
lower literacy materials if appropriate) advance care planning conversation 
about wishes, goals, and values for end-of-life care. Include the caregivers and 
especially the individual designated as the durable power of attorney for health 
care in the conversation. Talk about the difference between an advance 
directive and POLST and situations in which each would be acceptable. 
Document:  
 An advance directive that stipulates specific treatment preferences (if 
known and applicable to the situation),  
 A durable power of attorney for health care that names a surrogate and 
indicates the amount of leeway the surrogate should have in decision-
making, and  
 A written personal statement that articulates the patient’s values and 
goals regarding end-of-life care. 
 POLST, if appropriate.  
 Diagnostics should include:  
 Additional testing to validate diagnosis (see the Position Paper from the 
Dementia Action Collaborative) 
 Assessment of other treatable causes of cognitive impairment including: 
o Sleep apnea 
o Alcohol use (e.g., using the Alcohol Use Disorders Identification 
Test (AUDIT)) 
o Depression (e.g., using the Patient Health Questionnaire-9) 
o Overview of other medications that might impact cognition 
(e.g., benzodiazepines)  
 Laboratory testing to rule out treatable causes of cognitive impairment 
including a complete metabolic panel and other tests as clinically 
indicated.14  
 Additional dementia screening labs 
 Contingent labs (per patient history): RPR or MHA-TP, HIV, heavy metals 
 Imaging (e.g., CT, MRI) may be appropriate in certain situations as 
clinically indicated.  
 Assess activities of daily living and any patient, family, or other caregiver 
concerns.  
o Assess risk and quality of life  
 Inquire about driving status and safety (outlined here). 
 Assess hearing loss if not already done. 
 Inquire about home safety and assess for risk of falls 
 Assess for depression and risk of suicide 
 Discuss how to mitigate confusion, agitation, aggression, and/or wandering  
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 Assess for sleep quality and sleep disturbance  
 Review and manage medications 
 Caregiver stress, capacity, and support 
 After diagnosis, connect patient and family to appropriate local and/or state/national sources of 
care and support: 
o The county’s Area Agency on Aging provider (including referrals for family and caregiver 
support such as respite care facilities) 
o African American Elders Program 
o Alzheimer’s Association of Washington State 
o Alzheimer Society of Washington  
o American Association of Retired Persons (AARP) 
o American Automobile Association (AAA) Senior Drivers  
o Chinese Information and Service Center 
o Community Living Connections including resources by county 
o Momentia Seattle 
o National Institute on Aging  
o Open Doors for Multicultural Families 
o Seattle Indian Health Board 
o Path with Art 
 Provide a copy of or other access to the Washington State Dementia Action Collaborative’s 
Dementia Road Map: A Guide for Family and Care Partners  
Ongoing Care and Support/Management 
 Incorporate the dementia diagnosis and consideration for the patient’s cognitive function into 
shared decision making for routine medical care including into decisions about unnecessary or 
potentially harmful care (e.g., mammograms).  
 Continue to include the patient and family or other caregivers as part of the care team.  
o Look for signs of caregiver distress. Support caregivers and assess and note caregiver 
knowledge, skills, capacity and possible distress at each visit. Connect caregivers with 
available resources. 
 Identify the patient’s goals of care and work to maximize function that meet patient and family 
needs at each stage of the disease.  
 Work with health care team to appropriately treat conditions that can worsen symptoms or lead 
to poor outcomes, including depression and existing medical issues. 
 Routinely assess complexities of managing patients with dementia and the needs of family care 
partners for enhanced support.  
 Offer evidence-based dementia care management services (including home health, phone-
support and enhanced outpatient management) to patients and caregivers who have been 
determined to be high-risk. This high-risk group may include patients that have several medical 
comorbidities, complex medication regiments, behavioral/psychiatric symptoms, and/or history 
of frequent utilization of acute care services.   
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 Offer appropriate interventions. Level of support offered depends on patient-specific factors 
including complexity and severity of disease, comorbid health conditions, level of caregiver 
support, and other factors.  
o Educate family about the diagnosis and available treatment including the natural 
progression of dementia. 
 Talk about the benefit of cardiovascular exercise  
 Talk about the benefits of mindful changes to diet (e.g., increasing daily fruit and 
vegetable intake) 
o Discuss neuropsychiatric symptoms (e.g., agitation, psychosis) and management 
strategies using a shared-decision making approach appropriate to the patient. Manage 
with non-pharmacologic treatments first, consulting with behavioral health providers 
when possible.  
o Continue to offer information about available community supports.  
Planning for Higher Care Needs and Hospitalizations  
 Discuss possible red flags that may necessitate admission to an acute care setting as well as risks 
and benefits of hospitalization. 
 Discuss how to plan and prepare for a potential inpatient stay including risks and benefits of a 
hospitalization and when the patient may want to be hospitalized and when they may not want 
care in a hospital setting.  
 Monitoring for and communicate to the patient and family members about: 
o Progression of cognitive decline 
o Emergence of behavioral symptoms 
o Functional impairment (e.g., activities of daily living) 
o Care-partner/family capacity  
 Talk with patients and family about the potential need for receiving additional in-home supports 
or transitioning to a higher level of care (e.g., residential care facility) if care needs are greater 
than can be safely managed. Planning should include consideration for caregiver capacity, 
financial and insurance concerns (e.g., long term care coverage), health care considerations, and 
availability of local residential facilities, paid caregivers, and community resources (e.g., Meals 
on Wheels, volunteer chore services). 
 Be aware that delirium may be an issue after surgery. Talk about this risk with patients and 
family members.  
 
Advance Care Planning and Palliative Care 
 If not already done as part of the diagnostic process or completed earlier, have an empathetic, 
realistic, and patient- and family-centered (e.g., using lower literacy materials if appropriate) 
advance care planning conversation about wishes, goals, and values for end-of-life care. Include 
the caregivers and especially the individual designated as the durable power of attorney for 
health care in the conversation. Talk about the difference between an advance directive and 
POLST and situations in which each would be acceptable. Document:  
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o An advance directive that stipulates specific treatment preferences (if known and 
applicable to the situation),  
o A durable power of attorney for health care that names a surrogate and indicates the 
amount of leeway the surrogate should have in decision-making, and  
o A written personal statement that articulates the patient’s values and goals regarding 
end-of-life care. 
o POLST, if appropriate.  
 Discuss palliative care with the patient and family or other caregivers as well as whether or not 
hospice care might be appropriate.  
 Ensure that the patient and family know who to contact if symptoms (e.g., pain) develop or 
worsen. Ask if the patient and family feel confident in their care plan and work to fill any gaps.  
Residential Facilities 
 Provide regular dementia-specific training for staff, including environmental and non-
pharmacological interventions for neuropsychiatric symptoms. 
 Educate health care providers and staff on: 
o Symptoms of hearing loss and how to communicate with persons who have hearing loss. 
Information on how to communicate with someone who has hearing loss here. 
o How to have empathetic, realistic, and patient- and family-centered (e.g., using lower 
literacy materials if appropriate) advance care planning conversations. The difference 
between an advance directive and POLST, and patients for whom each would be 
acceptable. 
o How to refer patients to community-based advance care planning resources if 
appropriate. 
o Explaining the terms on an advance directive and POLST to family and friends at the end 
of a patient’s life  
o Supporting the patient, family, and friends during a time of crisis. 
 Work to promote discussions with residents about how to have conversations regarding 
personal goals of care and the type of care desired at the end of life with family members, 
friends, and health care providers; the importance of having an advance directive that includes a 
living will (also known as a health care directive), a durable power of attorney for health care, 
and a written personal statement about health care goals and values; and the difference 
between POLST and an advance directive. 
 Enter advance directives and/or POLST into the patient’s medical record once completed and 
communicate with the patient and his or her primary care provider as to whether the patient 
has advance directives and/or a POLST in his or her medical record.  
 Promote awareness of the value of palliative care and hospice and encourage appropriate 
hospice referrals. 
 Implement a quality improvement program to encourage greater adherence to patients’ 
requests as outlined in advance directives and POLST if accurate and applicable to the current 
situation. 
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 Measure family satisfaction with end-of-life care by widespread use of an after-death survey 
tool similar to that used by hospice agencies. 
 Support patients as they navigate care between different health care facilities and systems 
including facilitation of information sharing and patient and family outreach during times of 
crisis.  
Hospitals 
 Educate staff about Alzheimer’s disease and other dementias including on disease progression, 
care needs, communication, involving the family and other caregivers in decisions, and potential 
impact on hospitalization. 
 Screen all at-risk (e.g., ≥ 65 years old) patients on admission for risk of delirium using a brief 
cognitive test (e.g., Confusion Assessment Method or CAM) 
o If delirium is detected, provide targeted, multimodal prevention strategies aligned with 
the NICE clinical guidelines. This should include the use of bedside tests daily in the first 
days after surgery (e.g., Confusion Assessment Method-Intensive Care Unit or CAM-ICU, 
Delirium Detection Score).   
o Incorporate results into the medical record and confirm care team is aware of results. 
o Talk to the patient and family about the risk for delirium after surgery, what symptoms 
might look and feel like, management strategies, and what delirium might mean for 
recovery. 
 Be sure that all treating clinicians and other staff are aware of a patient’s dementia diagnosis 
and hearing loss and understand the patient’s communication ability, behavioral concerns (e.g., 
agitation, exit seeking, wandering), and other information that the patient may not be able to 
communicate (e.g., allergies, other reactions to medications, dietary preference). 
 Discharge 
o Support the patient and family members whether the patient is being discharged to a 
home or to a residential care or rehabilitation facility.  
o Assess family and caregiver support and feasibility of providing care at home (e.g., 
activities of daily living) including connecting to any available community supports (e.g., 
in-home services). Local and/or state/national sources of care and support may include:  
 The county’s Area Agency on Aging provider (including respite care referrals) 
 Alzheimer’s Association of Washington State 
 Alzheimer Society of Washington  
 American Association of Retired Persons (AARP) 
 American Automobile Association (AAA) Senior Drivers  
 Momentia Seattle 
 National Institute on Aging  
o If the patient is being discharged to a residential facility, identify facilities with vacancies 
and help the patient and family make a decision (e.g., meetings their needs, is certified 
by Medicare, is reasonable distance, has training or services specific to patients with 
cognitive impairment).  
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o Discuss factors like length of stay, cost, services to be conducted, and other patient 
questions. 
o The hospital team communicates with the facility or caregiver discharge instructions, 
current medications, and follow-up appointment needs.     
 Educate health care providers and staff on: 
o How to have empathetic, realistic, and patient- and family-centered (e.g., using lower 
literacy materials if appropriate) advance care planning conversations  
o How to be reimbursed for these conversations.  
o The difference between an advance directive and POLST, and patients for whom each 
would be acceptable. 
o How to refer patients to community-based advance care planning resources if 
appropriate. 
o Explaining the terms on an advance directive and POLST to family and friends at the end 
of a patient’s life  
o Supporting the patient, family, and friends during a time of crisis. 
 Review your facility’s protocols around asking about and honoring advance directives to 
decrease barriers to patients’ wishes being honored at the end of life. 
 Enter advance directives and/or POLST into the patient’s medical record once completed and 
communicate with the patient and his or her primary care provider as to whether the patient 
has advance directives and/or a POLST in his or her medical record.  
 Promote awareness of the value of palliative care, hospice, encourage appropriate hospice 
referrals, and be sure to communicate any referrals back to the patient’s primary care provider.  
 Support patients as they navigate care between different health care facilities and systems 
including facilitation of information sharing and patient and family outreach during times of 
crisis.  
Health Plans  
 Increase member awareness of how to maintain overall heart and brain health with age, about 
the difference between age-related changes in memory and the warning signs of dementia, and 
about the benefits of timely diagnosis of Alzheimer’s disease and other dementias. 
 Encourage hospitals, nursing homes, and other applicable settings to implement a quality 
improvement program focused on greater adherence to patients’ requests as outlined in 
advance directives and POLST if accurate and applicable to the current situation 
 Measure patient and family satisfaction with dementia care with use of a survey tool similar to 
that used by hospice agencies. 
 Develop inclusive and comprehensive benefits for patients with Alzheimer’s disease or other 
dementia allowing them to receive care consistent with their wishes and goals even if not 
eligible for hospice (e.g., palliative care).  
 Support patients as they navigate care between separate health care facilities and systems 
including facilitation of information sharing and patient and family outreach during crisis.  
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Employers 
 Recognize that many employees may be serving as informal caregivers to their family members 
or others. Incorporate caregiver supports into employee assistance programs.  
 Educate your employees about how to have conversations regarding personal goals of care and 
the type of care desired at the end of life with family members, friend, and health care 
providers; the importance of having an advance directive that includes a living will (also known 
as a health care directive), a durable power of attorney for health care, and a written personal 
statement about health care goals and values; and the difference between POLST and an 
advance directive. 
 Promote employee wellness by increasing awareness of how to maintain overall heart and brain 
health with age, about the difference between age-related changes in memory and the warning 




Washington State Health Care Authority  
 Promote awareness and utilization of advance care planning at multiple levels of health care 
delivery systems.  
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Diagnosis  
The workgroup recommends early detection of mild cognitive impairment (MCI) in order to better 
support the patient and family members but does not recommend population-level screening of older 
adults. Early detection supports patients and family members and allows patients and families to plan 
for future cognitive changes. The Dementia Action Collaborative has developed a clinical protocol for 
diagnosis, available here. 
The United States Preventive Services Task Force is currently updating their recommendation on 
screening for cognitive impairment in older adults. A previous review in 2013 found insufficient evidence 
to either recommend for or against population-level screening.15 While current data may be lacking to 
support comprehensive population-level screening, the workgroup’s expert opinion agrees with the 
potential benefits of early detection and supports efforts in this area. 
The Patient Protection and Affordable Care Act added an annual wellness visit as a new Medicare 
benefit in January 2011 requiring a health risk assessment and assessment of cognitive impairment (no 
specific tool is endorsed).16 The Alzheimer’s Association convened a workgroup to guide adoption of this 
inclusion, reviewing available evidence on validated tools to assess cognitive impairmenti and 
recommends using either the General Practitioner Assessment of Cognition (GPCOG), the Mini-Cog 
(repeating three unrelated words, performing clock drawing test, repeating the three unrelated words), 
or the Memory Impairment Screen (MIS) due to each being less than five minutes to administer, 
validated, easily administered by non-clinical 
staff, and free from bias and need for 
payment for copyright.17,18,19 Our Report and 
Recommendations does not review the 
specificity and sensitivity of the various 
screening tests as that has been done 
elsewhere. The Alzheimer’s Association 
developed a Medicare Annual Wellness Visit 
Algorithm for Assessment of Cognition, 
included in Appendix D. The workgroup 
endorses this algorithm as a best-practice 
clinical pathway and recommends this as the 
first step of a two-step process followed by 
further evaluation or formal cognitive testing 
with a longer instrument. Further evaluation 
can often be out of the scope of the annual 
wellness visit and can be done on the same day or as a new visit that may include family members or 
caregivers not present at the annual wellness visit. This two-step process is supported by the 
Alzheimer’s Association and is recommended due to being time-efficient.20  This second diagnostic step 
                                                          
i The Alzheimer’s Association reviewed: 7-Minute Screen, Abbreviated Mental Test, Blessed Orientation-Memory-Concentration 
Test (long and short), Cambridge Cognitive Examination, Clock Drawing Test, General Practitioner Assessment of Cognition, 
Mini-Cog, Memory Impairment Screen, Mini-Mental State Examination, Montreal Cognitive Assessment, Rowland Universal 
Dementia Assessment, Sweet Screening Instrument, The Short Portable Mental Status Questionnaire, Short Test of Mental 
Status, Time and Change Test 
Addressing Barriers 
The workgroup understands that time is one of the 
most significant barriers to addressing patient and 
family concern about memory loss and a diagnosis.  
CPT code 99483 was developed to reimburse 
separately for assessment and care plan development 
for Medicare beneficiaries with cognitive impairment. 
Find more information on background, 
implementation, and use from the Alzheimer’s 





 www.alz.org/careplanning/  
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can be done by the primary care provider or through a referral within or outside of the practice (e.g., to 
a neurologist, neuropsychologist). Caregiver(s) or other family members should be present for this visit.  
 
Ongoing Care and Support/Management  
Patient self efficacy is important for positive patient outcomes. The workgroup recommends working to 
instill hope in those diagnosed with dementia and their family members and other caretakers. Many 
diseases (e.g., pain, hypertension) have been shown to have increased positive outcomes with a positive 
patient mindset, including Alzheimer’s disease.21 The 2017 Lancet International Commission on 
Dementia, Prevention, Intervention, and Care focuses on nine modifiable risk factors (that contribute to 
about 35% of dementia cases) based on patient age: (1) early life: education to at least age 15; (2) mid-
life: reducing hypertension, obesity, and hearing loss; and (3) later life: reducing depression, managing 
diabetes, increasing physical activity, smoking cession, and increasing social contact.22 Intervening in 
these areas has been called a priority for public health.23 The link between cerebrovascular disease and 
dementia risk is well established, and should be part of conversations about prevention.24 The Lancet 
Commission also recommends individualized dementia care, supporting caregivers, end-of-life care 
planning, and planning for future care needs, among others.25  
Interventions 
Pharmacologic treatment approved for Alzheimer’s disease and recommended by the American 
Academy of Neurology, The American College of Physicians, the American Academy of Family Physicians, 
the American Psychiatric Association, and the American Geriatric Society include cholinesterase 
inhibitors or memantine for patients diagnosed with Alzheimer’s disease after a discussion with the 
patient about risks and benefits.26,27 While clinical research into experimental drugs targeting the 
proteins associated with cognitive decline have recently not met with success, the most promising 
interventions include exercise and diet modification.28 
The Agency for Healthcare Research and Quality conducted a systematic review of interventions to 
prevent age-related cognitive decline, cognitive impairment, and clinical Alzheimer’s type-dementia, 
completed March 2017.29 Interventions under review included “cognitive training, physical activity, 
nutraceuticals, diet, multimodal interventions, hormone therapy, vitamins, antihypertensive treatment, 
lipid lowering treatment, nonsteroidal anti-inflammatory drugs (NSAIDs), antidementia drugs, diabetes 
treatment, and other.” Analysis found no high-strength evidence to delay or prevent cognitive decline, 
medium strength evidence that cognitive training has positive effects on adults with presumed normal 
cognition, and weak evidence for cognitive training on adults with clinical Alzheimer’s disease or other 
dementias. Other interventions such as vitamins (e.g., vitamin E in women, B12 plus folic acid) were 
associated with positive outcomes (weak evidence) with a general trend toward efficacy for physical 
activity and vitamin B12 plus folic acid.  
Other systematic reviews have focused on specific interventions and found more promising results. 
Exercise has been shown to be associated with a reduction in the risk of diagnosis with Alzheimer’s 
disease and in some studies to be associated with improved cognition and balance after diagnosis.30,31 
Specific diets high in vitamin E, B vitamins, and the n-3 fatty acid and low in saturated fat have also been 
associated with slowed cognitive decline.32 The Mediterranean–DASH Intervention for 
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Neurodegenerative Delay, based on the Dietary Approaches to Stop Hypertension diet, has been shown 
to be associated with slower rates of cognitive decline and lower incidence of Alzheimer’s disease.33,34,35  
Other multimodal interventions, including the Finnish Geriatric Intervention Study to Prevent Cognitive 
Impairment and Disability (FINGER) study that include a combination of nutritional guidance, exercise, 
cognitive training, social activity, and management of metabolic and vascular risk factors have been 
shown to be associated with a reduction in cognitive decline or maintenance of function.36 These 
multimodal interventions are more difficult to adopt in the United States health care environment, but 
elements may be suited for widespread use.   
Communication and shared-decision making, advance care planning and care goals, and keeping the 
patient at the center of care have been identified by other researchers as key goals for palliative care for 
patients with dementia.37 However, inclusion of palliative care into guidelines for patients with 
dementia has significant gaps, with less attention to end of life care than to other areas, especially 
around grief.38 
 
Palliative Care and End of Life Care 
This workgroup draws on the Bree Collaborative’s previous work around end-of-life care. The Bree 
Collaborative convened a workgroup that met from January to November 2014. The workgroup’s goal is 
that all Washingtonians be informed about their end-of-life options, communicate their preferences in 
actionable terms, and receive end-of-life care that is aligned with their wishes, goals, and values. The 
workgroup to developed the following five focus areas corresponding to how an individual would ideally 
experience advance care planning for the end of life. These focus areas work to empower patients to 
voice their wishes and make sure that the care that all Washingtonians receive at the end of life is the 
care that they and their families want. The recommendations are highly aligned with this workgroup. 
Read the Report here and see focus areas below:  
1. Increase awareness of advance care planning, advance directives, and Physician Orders for Life Sustaining 
Treatment (POLST) in Washington State 
2. Increase the number of people who participate in advance care planning in the clinical and community 
settings    
3. Increase the number of people who record their wishes and goals for end-of-life care using documents 
that: accurately represent their values; are easily understandable by all readers including family members, 
friends, and health care providers; and can be acted upon in the health care setting 
4. Increase the accessibility of completed advance directives and POLST for health systems and providers 
5. Increase the likelihood that a patient’s end-of-life care choices are honored  
 
Transitions of Care 
The workgroup framed transitions of care from a patient perspective, acknowledging that patients and 
family members will need to both think about (1) increasing needs for care and support at home, (2) 
transitions from the home into higher levels of care, and (3) that hospitalization may occur and the 
patient may then need to transition from the hospital to either the home or to a residential care facility.  
Care transitions can be stressful for the patient and family, and if not well managed can result in patient 
safety issues and poor care outcomes.39 Health professionals report need for discharge planning for 
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patients with dementia to routinely exceed supply with critical issues around communication with other 
care settings and around medication.40 Patients admitted to the inpatient setting are often not assessed 
for dementia and staff can be untrained on how to safely manage patients with dementia.41 Guidelines 
for patients stress the importance of pre-planning for a potential hospital admission and for protocols 
that support patient assessment of dementia and planned next steps to mitigate behavioral concerns 
and patient safety issues (e.g., wandering).42 
 
Delirium 
Delirium is an acute change in cognition and attention defined in the DSM-V as “Disturbance in attention 
(i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to 
the environment) [that] develops over a short period of time (usually hours to a few days), represents an 
acute change from baseline attention and awareness, and tends to fluctuate in severity during the 
course of a day.”43 Delirium is not due to a preexisting condition, but cognitive impairment is a risk 
factor as is depression and functional status, and can cause poor health outcomes, stress for family 
members and other caregivers, and can be underdiagnosed. 44 Delirium has been associated with an 
increased risk of death and risk of institutionalization, independent of baseline dementia.45 As many as 
52% (range 37-52%) of elderly patients undergoing cardiac surgery and 65% (25-65%) undergoing hip 
replacement have experienced delirium.46  
The National Institute for Health and Clinical Excellence (NICE) developed a Guideline for Prevention of 
Delirium including 13 clinical recommendations for hospitalized patients and for at-risk adults in long-
term care settings, listed in Appendix F.47 The workgroup endorses these clinical recommendations and 
recommends that at-risk patients be screened for delirium using a brief cognitive test (e.g., CAM) to 
allow for risk assessment of post-operative delirium and as a comparison to post-surgical testing. If 
delirium is detected, the workgroup recommends targeted, multimodal prevention strategies aligned 
with the NICE clinical guidelines. This should include the use of bedside tests daily in the first days after 
surgery (e.g., Confusion Assessment Method-Intensive Care Unit (CAM-ICU), Delirium Detection 
Score).48 Family and other caregivers should be provided with education and appropriate coping skills to 
recognize and manage delirium.49 
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Other Work in Washington State  
Developing a Washington State Plan  
Governor Jay Inslee convened a Washington State Aging Summit in 2013 with leaders from public and 
private sectors around the need for a Washington State-specific Alzheimer’s disease state plan. The 
Legislature answered this charge in 2014 with Senate Bill 6124 that created a taskforce, the Alzheimer’s 
Disease Working Group, to look at the needs of those with Alzheimer’s disease and other dementias, 
services within Washington State to meet needs, and projecting future population-level needs and 
system capacity.50 The Working Group released the Alzheimer’s State Plan in January 2016 including: 
 Goals – Broad visionary statements 
 Strategies – High-level plans to achieve the goals 
 Recommendations – Specific responses or actions 
Read the Washington State Plan to Address Alzheimer’s Disease and Other Dementias 
 
Like the State Plan, this Report and Recommendations is based on a public-private framework, builds on 
previous work that is person and family-centered, and that takes a life-course approach. The 
Washington State Plan contains much more comprehensive epidemiological information than this 
Report and Recommendations. We encourage those interested in further information to consult the 
State Plan.  
 
The Dementia Action Collaborative (DAC) formed in April 2016 to implement the State Plan through a 
focus on: (1) public awareness and community readiness, (2) long-term services and supports, and (3) 
health and medical best practices. A public-private partnership made up of 37 stakeholders representing 
those with dementia, family caregivers, medical providers, researchers, Legislators, Washington State 
Agency staff, and support organizations, the DAC prioritized recommendations that could be 
accomplished through heightened collaboration and within existing state resources, that could sustain 
momentum and awareness through partnerships. The Bree Collaborative was engaged as a partner in 
July of 2016 and selected Alzheimer’s disease and Other Dementias as a topic around which to develop 
clinical recommendations. This builds from the health and medical subcommittee action item to 
convene an expert panel to identify and endorse evidence-based standards for diagnosis, treatment, 
supportive care, and advanced planning.  
 
 Learn more about the Dementia Action Collaborative. 
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Measurement  
We encourage organizations to operationalize metrics as relevant to their organization. Healthy People 
2020 includes two Alzheimer’s disease and other dementias related metrics:  
 Diagnosis awareness among persons with Alzheimer's disease and other dementias or their 
caregiver (percent, 65+ years) 
 Preventable hospitalizations among persons with Alzheimer's disease and other dementias 
(percent, 65+ years) 
The American Academy of Neurology proposes has proposed nine metrics to measure quality of care for 
those with Alzheimer’s disease and other dementias.51 Many of these measures are aligned with the 
focus areas of this set of recommendations.  
Table 2: American Academy of Neurology Proposed Metrics for Those with Alzheimer’s Disease and 
Other Dementias 
Title Description 
1. Disclosure of dementia 
diagnosis 
Percentage of patients with a diagnosis of a qualifying dementing disorder or 
disease whose diagnosis has been disclosed to them and, if available, their primary 
caregiver 
2. Education and support of 
caregivers for patients 
with dementia 
Percentage of patients with dementia whose caregivers were provided with 
education on dementia disease management and health behavior changes and 
were referred to additional resources for support in the last 12 months 
3. Functional status 
assessment for patients 
with dementia 
Percentage of patients with dementia for whom an assessment of functional status 
was performed at least once in the last 12 months 
4. Screening and 
management of 
behavioral and psychiatric 
symptoms associated 
with dementia (BPSD) 
Percentage of patients with dementia for whom there was a documented 
screening for behavioral and psychiatric symptoms, including depression, and for 
whom, if screening positive, there was also documentation of recommendations 
for management in the last 12 months 
5. Safety concern screening 
and follow-up for patients 
with dementia 
Percentage of patients with dementia or their caregivers for whom there was a 
documented safety screening in 2 domains of risk, dangerousness to self or others 
and environmental risks, and for whom, if screening positive, there was 
documentation they were provided with recommendations for their mitigation, 
which may include referral to other resources, in the last 12 months 
6. Driving screening and 
follow-up for patients 
with dementia 
Percentage of patients with dementia for whom there was a documented 
screening for driving risks and for whom, if screening positive, there was also 
documentation they were informed of alternatives to driving in the last 12 months 
7. Advance care planning 
and palliative care 
counseling for patients 
with dementia 
Percentage of patients with dementia who have an advance care plan or surrogate 
decision-maker documented in the medical record or documentation in the 
medical record that an advance care plan was discussed but the patient did not 
wish or was not able to name a surrogate decision-maker or provide an advance 
care plan and percentage of patients with dementia or their surrogate decision-
maker who received comprehensive counseling regarding ongoing palliation and 
symptom management and end-of-life decisions within 2 years of initial diagnosis 
or assumption of care 
8. Pain assessment and 
follow-up for patients 
with dementia 
Percentage of patients with dementia who underwent documented screening for 
pain symptoms at every visit and if screening positive also had a documentation of 
a follow-up plan 
9. Pharmacologic treatment 
of dementia 
Percentage of patients with dementia or their caregivers with whom available 
guideline-appropriate pharmacologic treatment options and nonpharmacological 
behavior and lifestyle modifications were discussed at least once in the last 12- 
month period 
Sanders A, Nininger J, Absher J, Bennett A, Shugarman S, Roca R. Quality improvement in neurology: Dementia management 
quality measurement set update. Neurology. 2017 May 16;88(20):1951-1957. 
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Appendix A: Bree Collaborative Members 
Member Title Organization 
Susie Dade MS Deputy Director Washington Health Alliance 
John Espinola MD, MPH Executive Vice President, 
Health Care Services 
Premera Blue Cross 
Gary Franklin MD, MPH Medical Director Washington State Department 
of Labor and Industries 
Stuart Freed MD Chief Medical Officer Confluence Health 
Richard Goss MD Medical Director Harborview Medical Center – 
University of Washington 
Jennifer Graves, RN, MS Senior Vice President, Patient 
Safety 
Washington State Hospital 
Association 
Christopher Kodama MD President, MultiCare 
Connected Care 
MultiCare Health System 
Daniel Lessler MD, MHA Chief Medical Officer Washington State Health Care 
Authority 
Paula Lozano MD, MPH Associate Medical Director, 
Research and Translation 
Kaiser Permanente 
Wm. Richard Ludwig MD Chief Medical 
Officer, Accountable Care 
Organization 
Providence Health and Services 
Greg Marchand Director, Benefits & Policy 
and Strategy 
The Boeing Company 
Robert Mecklenburg MD Medical Director, Center for 
Health Care Solutions 
Virginia Mason Medical Center 
Kimberly Moore MD Associate Chief Medical 
Officer 
Franciscan Health System 
Carl Olden MD Family Physician Pacific Crest Family Medicine, 
Yakima 
Mary Kay O’Neill MD, MBA Partner Mercer 
John Robinson MD, SM Chief Medical Officer First Choice Health 
Terry Rogers MD (Vice Chair) Chief Executive Officer Foundation for Health Care 
Quality 
Jeanne Rupert DO, PhD Medical Director, Community 
Health Services 
Public Health – Seattle and King 
County 
Kerry Schaefer Strategic Planner for 
Employee Health 
King County 
Bruce Smith MD Medical Director Regence Blue Shield 
Lani Spencer RN, MHA Vice President, Health Care 
Management Services 
Amerigroup 
Hugh Straley MD (Chair) Retired Medical Director, Group Health 
Cooperative; President, Group 
Health Physicians 
Shawn West MD Family Physician Edmonds Family Medicine 
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Appendix B: Alzheimer’s Disease and Other Dementias Workgroup Charter and Roster 
Problem Statement  
Washington State has the third highest rate of death from Alzheimer’s disease of any state.1iiThis is 
expected to increase 40% in next 10 years and 181% over the next 30 years.1 In many practices in 
Washington State, there are no guidelines to increase quality of care for screening, diagnosis, or 
treatment of Alzheimer’s disease and other dementias.2iiiThis is costly to the health care system and 
overly burdensome to primary care clinicians, and patients, their caregivers, and the community.  
 
Aim 
To align care delivery with existing evidence-based standard of care for diagnosis, treatment, supportive 
care, and advanced care planning within primary care for patients with Alzheimer’s disease or other 
dementias and their families and caregivers while decreasing variation in quality of treatment across the 
state of Washington.  
 
Purpose 
To propose evidence-based recommendations to the full Bree Collaborative on: 
 Aligning with the Alzheimer’s State Plan and the Alzheimer’s Disease Working Group. 
 Diagnostic tools for Alzheimer’s disease and other dementias. 
 Offering supportive care to patients and their family and other caregivers including medication 
management and managing co-morbid conditions. 
 Support with late-stage dementia and advance care planning. 
 Referring to other resources such as counseling, senior day programs, or palliative care of those 
with dementia. 
 Identifying other areas of focus. 
 
Duties & Functions 
The Alzheimer’s Disease and Other Dementias workgroup will: 
 Research evidence-based guidelines and best practices (emerging and established).  
 Consult relevant professional associations and other stakeholder organizations and subject 
matter experts for feedback, as appropriate.  
 Meet for approximately nine months, as needed.  
 Provide updates at Bree Collaborative meetings. 
 Post draft report(s) on the Bree Collaborative website for public comment prior to sending report 
to the Bree Collaborative for approval and adoption. 
 Present findings and recommendations in a report. 
 Recommend data-driven and practical implementation strategies.  
 Create and oversee subsequent subgroups to help carry out the work, as needed. 
                                                          
1iiAlzheimer’s Association. Alzheimer’s Statistics Washington. Available: 
www.alz.org/documents_custom/facts_2016/statesheet_washington.pdf  
2iiiWashington State Department of Social and Health Services. Washington State Plan to Address Alzheimer’s Disease and Other Dementias. 
January 1, 2016. Available: 
www.dshs.wa.gov/sites/default/files/SESA/legislative/documents/2016%20WA%20Alzheimer%27s%20State%20Plan%20-
%20Full%20Report%20Final.pdf  
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 Revise this charter as necessary based on scope of work.  
 
Structure 
The workgroup will consist of individuals confirmed by Bree Collaborative members or appointed by the 
chair of the Bree Collaborative or the workgroup chair. 
The chair of the workgroup will be appointed by the chair of the Bree Collaborative. 
The Bree Collaborative program director will staff and provide management and support services for the 
workgroup. 
Less than the full workgroup may convene to: gather and discuss information; conduct research; analyze 
relevant issues and facts; or draft recommendations for the deliberation of the full workgroup.  A quorum 




The workgroup will hold meetings as necessary. The program director will conduct meetings along with 
the chair, arrange for the recording of each meeting, and distribute meeting agendas and other materials 
prior to each meeting. Additional workgroup members to be added at the discretion of the chair.  
 
Name Title Organization 
Kristoffer Rhoads, PhD 
(Chair) 
Primary Neuropsychologist, 
Memory and Brain Wellness 
Center 
University of Washington Medical 
Center 
Kimiko Domoto-Reilly, MD Alzheimer's Research Center  University of Washington Medical 
Center 
Richard Furlong, MD Primary Care Virginia Mason Medical Center 
Barak Gaster, MD  Professor of Medicine University of Washington Medical 
Center 
Kelly Green, MSW Social Worker Evergreen Health  
Debbie Hunter Family Caregiver 
Nancy Isenberg, MD, MPH, 
FAAN 
Neurologist, Clinical Associate 
Professor of Neurology, Center 
for Healthy Aging & Memory 
Virginia Mason Medical Center 
Arlene Johnson Family Caregiver 
Kerry Jurges, MD Primary Care Confluence Health 
Eric Larson, MD, MPH Vice President for Research and 
Health Care Innovation 
Kaiser Foundation Health Plan of 
Washington 
Todd Larson Family Caregiver 
Myriam Marquez   Patient Advocate 
Shirley Newell, MD Chief Medical Officer Aegis Living 
Darrell Owens, DNP, ARNP Clinic Chief, Director University of Washington 
Outpatient Primary, Palliative and 
Supportive Care Program 
Tatiana Sadak, PhD, ARNP Psychiatric Nurse Practitioner Associate Professor of Geriatric 
Mental Health, University of 
Washington School of Nursing 
Bruce Smith, MD Medical Director Regence Blue Shield 
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Appendix C: Guideline and Systematic Review Search Results  




(2017) Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive 
Impairment, and Clinical Alzheimer’s-Type Dementia 




(2017) The use of vitamin E in the treatment of mild cognitive impairment and 
Alzheimer's disease (AD) 
(2017) Proteins in cerebrospinal fluids (CSF) for early prediction of developing 
Alzheimer’s disease or other dementia in people with mild cognitive problems 
(2017) Is dance movement therapy an effective intervention for dementia? A 
review of the evidence 
(2016) Medicines for sleep problems in dementia 
(2016) Treatment of epilepsy for people with Alzheimer's disease 
(2016) Statin withdrawal in people with dementia 
(2016) Omega-3 fatty acids for the treatment of dementia 
(2016) Mini-Mental State Examination (MMSE) for the detection of dementia in 
people aged over 65 
(2016) Statins for the prevention of dementia 
(2015) Montreal Cognitive Assessment (MoCA) for the diagnosis of Alzheimer's 
disease and other dementias 
(2015) Rivastigmine for people with Alzheimer's disease 
(2015) Regional Cerebral Blood Flow SPECT for detection of Frontotemporal 
dementia in people with suspected dementia 
(2015) Dimebon for Alzheimer's disease 
(2015) Baseline scores of Mini-Mental State examination (MMSE) for early 
prediction of developing dementia in people with mild cognitive impairments 
(MCI) 
(2015) Cholinesterase inhibitors for rarer dementia associated with neurological 
conditions 
(2015) A brief cogntive screening test (Mini-Cog) for the assessment of possible 
dementia 
(2015) Dopamine transporter imaging for the diagnosis of dementia with Lewy 
bodies 
(2015) ¹⁸F-FDG PET scan for early prediction of developing Alzheimer’s disease or 
other dementia in people with mild cognitive impairment (MCI) 
(2014) 11C-PIB-PET scan for early prediction of developing Alzheimer’s disease or 
other dementia in people with mild cognitive impairment (MCI) 
(2014) Statins for the treatment of Alzheimer's disease 
(2014) Proteins in blood and cerebrospinal fluids for early prediction of 
developing Alzheimer’s disease or other dementia in people with cognitive 
problems 
(2014) There is no evidence that MPACs (PBT1 or PBT2) are of benefit in 
Alzheimer's dementia 
(2014) Management of faecal incontinence and constipation in adults with central 
nervous system diseases 
(2013) Cognitive training and cognitive rehabilitation for mild to moderate 
Alzheimer's disease and vascular dementia 
(2013) Rivastigmine for vascular cognitive impairment 
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(2013) Withdrawal of chronic antipsychotic drugs for behavioural and 
psychological symptoms in older people with dementia 
(2013) Cerebrolysin for vascular dementia 
(2012) No evidence from randomised controlled trials for or against the use of 
huperzine A in the treatment of people with mild cognitive impairment 








 (2016) The American Psychiatric Association practice guideline on the use of 
antipsychotics to treat agitation or psychosis in patients with dementia. 
(2016) Canadian Task Force on Preventive Health Care Recommendations on 
screening for cognitive impairment in older adults. 
(2015) American Geriatrics Society American Geriatrics Society 2015 updated 
Beers Criteria for potentially inappropriate medication use in older adults. 
(2014 revised) American College of Radiology ACR Appropriateness Criteria® 
dementia and movement disorders. 
(2014 revised) U.S. Preventive Services Task Force Final Recommendation 
Statement Cognitive Impairment in Older Adults: Screening 
(2014) American Occupational Therapy Association, Inc. Occupational therapy 
practice guidelines for home modifications. 
(2013 revised) University of Iowa College of Nursing, John A. Hartford Foundation 
Center of Geriatric Nursing Excellence Bathing persons with dementia. 
(2013) Alzheimer's Association, Society of Nuclear Medicine and Molecular 
Imaging Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging 
Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the 
Alzheimer's Association. 
(2013) Alzheimer's Association Alzheimer's Association recommendations for 
operationalizing the detection of cognitive impairment during the Medicare 
Annual Wellness Visit in a primary care setting. 
(2012 revised) Hartford Institute for Geriatric Nursing Recognition and 
management of dementia. 
(2012 revised) American Medical Directors Association Dementia in the long term 
care setting. 
(2012 revised) Hartford Institute for Geriatric Nursing Assessing cognitive 
functioning. In: Evidence-based geriatric nursing protocols for best practice. 
(2012 revised) Hartford Institute for Geriatric Nursing Assessment and 
management of mealtime difficulties. 





(2014) Functional neuroimaging for primary degenerative dementia or mild 
cognitive impairment “Functional neuroimaging for primary degenerative 
dementia or mild cognitive impairment is not covered. Functional imaging 
technologies including: fludeoxyglucose (FDG) Positron Emission Tomography 
(PET), (11)C-dihydrotetrabenazine (C-DTBZ) PET, Single Photon Emission 
Computed Tomography (SPECT), Functional Magnetic Resonance Imaging (fMRI) 




and Prevention  
Information: What is Alzheimer’s Disease? 
Information: Healthy Brain Initiative 
National Institute 
on Aging  
Information: Alzheimer's Disease & Related Dementias 
















(2011) A Systematic Evidence Review of Non-pharmacological Interventions for 
Behavioral Symptoms of Dementia 
(2010) A Systematic Evidence Review of Interventions for Non-professional 
Caregivers of Individuals with Dementia 
(2010) A Systematic Evidence Review of the Signs and Symptoms of Dementia and 
Brief Cognitive Tests Available in VA 
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Appendix D: Alzheimer’s Association Medicare Annual Wellness Visit Algorithm for 
Assessment of Cognition 
Source: Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Alzheimer’s 
Association recommendations for operationalizing the detection of cognitive impairment during the 
Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013 Mar;9(2):141-50. 
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Appendix E: Alzheimer’s Association Principles for a Dignified Diagnosis  
Source: Alzheimer’s Association. Principles for a Dignified Diagnosis. Available: 
www.alz.org/national/documents/brochure_dignified_diagnosis.pdf  
Talk to me, the person living with dementia, directly. I am the person living with the disease, and 
though those close to me will also be affected, I am the person who needs to know first.  
Tell the truth. Even if you don’t have all of the answers, be honest about what you do know and why 
you believe it to be so. 
Test early. Helping me get an accurate diagnosis as soon as possible gives me more time to cope, live to 
my fullest potential and access information and resources.  
Take my memory concerns seriously, regardless of my age. Age may be the biggest risk factor for 
Alzheimer’s, but Alzheimer’s is not a normal part of aging. Don’t discount my concerns because of my 
age. At the same time, don’t forget that the disease can also affect people in their 40s, 50s and 60s.  
Deliver the diagnosis in plain but sensitive language. My diagnosis may be one of the most important 
things I ever hear. Please use language that I can understand and be sensitive to how this may make me 
feel.  
Coordinate with other care providers. I may be seeing more than one doctor. It’s important that you 
talk to my other care providers to ensure everyone has the information so that changes can be 
identified early and I won’t have to repeat tests unnecessarily. 
Explain the purpose of different tests and what you hope to learn. Testing can be very physically and 
emotionally challenging. It would help me to know the purpose of the test, how long it will take and 
what you expect to learn from the process. I would also appreciate the option of breaks during longer 
tests and an opportunity to ask questions.  
Give me tools for living with this disease. Please don’t give me my diagnosis and then leave me alone to 
confront it. I need to know what will happen to me, what medical treatments are available, and what 
support and resources are offered through the Alzheimer’s Association® and my community.  
Work with me on a plan for living a quality life. Medication may help modify some of my neurological 
symptoms, but I am also interested in recommendations for keeping myself as healthy as possible 
through diet, exercise and social engagement.  
Recognize that I am an individual and the way I experience this disease is unique. This disease affects 
each person in different ways and at a different pace. Please be sure to couch your explanation of how 
this disease may change my life with this in mind. 
Alzheimer’s is a journey, not a destination. Treatment doesn’t end with the writing of a prescription. 
Please continue to be an advocate — not just for my medical care but for my quality of life as I continue 
to live with Alzheimer’s disease. 
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Appendix F: NICE Guideline for Prevention of Delirium 
Source: O'Mahony R, Murthy L, Akunne A, Young J; Guideline Development Group. Synopsis of the National 
Institute for Health and Clinical Excellence guideline for prevention of delirium. Ann Intern Med. 2011 Jun 
7;154(11):746-51. Available here.  
1. Ensure that persons at risk for delirium are cared for by a team of health care professionals who are 
familiar with the person at risk. Avoid moving persons within and between wards or rooms unless 
absolutely necessary. 
2. Give a tailored, multicomponent intervention package. Within 24 hours of hospitalization, assess 
persons at risk for clinical factors contributing to delirium. On the basis of the results of this 
assessment, provide a multicomponent intervention tailored to the person’s individual needs and 
care setting.  
3. The tailored, multicomponent intervention package should be delivered by a multidisciplinary team 
trained and competent in delirium prevention. 
4. Address cognitive impairment or disorientation by providing appropriate lighting and clear signage, 
ensuring that a clock (consider providing a 24-hour clock in the critical care unit) and a calendar are 
easily visible to the person at risk; talking to the person to reorient them by explaining where they 
are, who they are, and what your role is; introducing cognitively stimulating activities (for example, 
reminiscence); and facilitating regular visits from family and friends. 
5. Address dehydration and constipation by ensuring adequate fluid intake to prevent dehydration by 
encouraging the person to drink—consider offering subcutaneous or intravenous fluids, if necessary, 
and taking advice when managing fluid balance in persons with comorbid conditions (for example, 
heart failure or chronic kidney disease). 
6. Assess for hypoxia and optimize oxygen saturation, if necessary, as clinically appropriate. 
7. Address infection by looking for and treating infection, avoiding unnecessary catheterization, and 
implementing infection-control procedures in line with the NICE clinical guideline on infection 
control (13). 
8. Address immobility or limited mobility through the following actions: Encourage persons to mobilize 
soon after surgery and walk (provide appropriate walking aids that are accessible at all times) and 
encourage all persons, including persons who are unable to walk, to carry out active, range-of-
motion exercises. 
9. Address pain by assessing for pain; looking for nonverbal signs of pain, particularly in persons with 
communication difficulties (for example, persons with learning difficulties or dementia or persons on 
a ventilator or who have a tracheostomy); and initiating and reviewing appropriate pain 
management in any person in whom pain is identified or suspected. 
10. Carry out a medication review for persons receiving several drugs, taking into account both the type 
and the number of medications. 
11. Address poor nutrition by following the advice given in the nutrition support in adults section in the 
NICE clinical guideline  and ensuring that dentures fit properly in persons who have them. 
12. Address sensory impairment by resolving any reversible cause of the impairment, such as impacted 
ear wax, and ensuring hearing and visual aids are available to and used by persons who need them, 
and check that such aids are in good working order. 
13. Promote good sleep patterns and sleep hygiene by avoiding nursing or medical procedures during 
sleeping hours, if possible; scheduling medication rounds to avoid disturbing sleep; and reducing 
noise to a minimum during sleep periods. 
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